Literature DB >> 12825933

Development of natural product-derived receptor tyrosine kinase inhibitors based on conservation of protein domain fold.

Lars Kissau1, Petra Stahl, Ralph Mazitschek, Athannasios Giannis, Herbert Waldmann.   

Abstract

Receptor tyrosine kinases (RTKs) such as Tie-2, IGF1R, Her-2/Neu, EGFR, and VEGFR1-3 play crucial roles in the control of cell growth and differentiation. Inhibition of such RTKs has become a major focus of current anticancer drug development, and therefore the discovery of new classes of inhibitors for these signal-transducing proteins is of prime importance. We have recently proposed a novel concept for improving the hit-finding process by employing natural products as biologically validated starting points in structural space for compound library development. In this concept, natural products are regarded as evolutionary chosen ligands for protein domains which are structurally conserved yet genetically mobile. Here we report on the discovery of novel and highly selective VEGFR-2 and -3, Tie-2, and IGF1R inhibitors derived from the naturally occurring Her-2/Neu kinase inhibitor nakijiquinone C and developed on the basis of this concept. Based on the structure of the natural product, a small library (74 members) was synthesized and investigated for inhibition of kinases with highly similar ATP-binding domains. The library yielded inhibitors with IC(50)s in the low micromolar range with high frequency (7 out of 74). In particular, four inhibitors of Tie-2 were found, a kinase critically involved in the formation of new blood vessels from preexisting ones (angiogenesis) and believed to be a new promising target in antitumor therapy. These results support the "domain concept". To advance the development of improved inhibitors, extensive molecular modeling studies were undertaken, including the construction of new homology models for VEGFR-2 and Tie-2. These studies revealed residues in the kinase structure which are crucial to the development of tailor-made receptor tyrosine kinase inhibitors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12825933     DOI: 10.1021/jm0307943

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

Review 1.  Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.

Authors:  Pushpendra Singh; Jimi Marin Alex; Felix Bast
Journal:  Med Oncol       Date:  2013-12-14       Impact factor: 3.064

2.  Structural simplification of bioactive natural products with multicomponent synthesis. 3. Fused uracil-containing heterocycles as novel topoisomerase-targeting agents.

Authors:  Nikolai M Evdokimov; Severine Van Slambrouck; Petra Heffeter; Lee Tu; Benjamin Le Calvé; Delphine Lamoral-Theys; Carla J Hooten; Pavel Y Uglinskii; Snezna Rogelj; Robert Kiss; Wim F A Steelant; Walter Berger; Jeremy J Yang; Cristian G Bologa; Alexander Kornienko; Igor V Magedov
Journal:  J Med Chem       Date:  2011-03-09       Impact factor: 7.446

3.  Helianthin induces antiproliferative effect on human glioblastoma cells in vitro.

Authors:  Oana Alexandru; Laura Dragutescu; Ligia Tataranu; Vasile Ciubotaru; Ani Sevastre; Ada Maria Georgescu; Oana Purcaru; Suzana Danoiu; L Magnus Bäcklund; Anica Dricu
Journal:  J Neurooncol       Date:  2010-07-16       Impact factor: 4.130

Review 4.  40 Years of Research on Polybrominated Diphenyl Ethers (PBDEs)-A Historical Overview and Newest Data of a Promising Anticancer Drug.

Authors:  Laura Schmitt; Ilka Hinxlage; Pablo A Cea; Holger Gohlke; Sebastian Wesselborg
Journal:  Molecules       Date:  2021-02-13       Impact factor: 4.411

Review 5.  Kinase inhibitors from marine sponges.

Authors:  Danielle Skropeta; Natalie Pastro; Ana Zivanovic
Journal:  Mar Drugs       Date:  2011-10-24       Impact factor: 6.085

Review 6.  Marine Sponges and Bacteria as Challenging Sources of Enzyme Inhibitors for Pharmacological Applications.

Authors:  Nadia Ruocco; Susan Costantini; Flora Palumbo; Maria Costantini
Journal:  Mar Drugs       Date:  2017-06-12       Impact factor: 5.118

Review 7.  A Brief Overview of Two Major Strategies in Diversity-Oriented Synthesis: Build/Couple/Pair and Ring-Distortion.

Authors:  Sihyeong Yi; Begur Vasanthkumar Varun; Yoona Choi; Seung Bum Park
Journal:  Front Chem       Date:  2018-10-22       Impact factor: 5.221

Review 8.  Understanding the Key to Targeting the IGF Axis in Cancer: A Biomarker Assessment.

Authors:  Kunal Amratlal Lodhia; Piyawan Tienchaiananda; Paul Haluska
Journal:  Front Oncol       Date:  2015-07-08       Impact factor: 6.244

9.  Revisiting the IGF-1R as a breast cancer target.

Authors:  Roudy Chiminch Ekyalongo; Douglas Yee
Journal:  NPJ Precis Oncol       Date:  2017-05-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.